Amphastar Pharma Q2Adj EPS $0.65 Beats $0.56 Estimate, Sales $145.71M Beat $137.37M Estimate
Portfolio Pulse from saritha@benzinga.com
Amphastar Pharma reported Q2 earnings of $0.65 per share, beating the analyst consensus estimate of $0.56 by 16.07%. This is a 66.67% increase from the same period last year. The company also reported quarterly sales of $145.71 million, beating the analyst consensus estimate of $137.37 million by 6.07%. This is an 18.02% increase from the same period last year.
August 08, 2023 | 8:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Amphastar Pharma's Q2 earnings and sales exceeded analyst estimates, indicating a strong financial performance.
Amphastar Pharma's Q2 earnings and sales have significantly exceeded analyst estimates, which is a positive signal for the company's financial performance. This could lead to increased investor confidence and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100